HIF-1 as a target for drug development
The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
Abstract
Sensing and responding to fluxes in oxygen tension is perhaps the single most important variable in physiology, and animal tissues have developed a number of essential mechanisms to cope with the stress of low physiological oxygen levels, or hypoxia. Among these coping mechanisms is the response mediated by the hypoxia-inducible transcription factor, or HIF-1. HIF-1 is an essential component in changing the transcriptional repertoire of tissues as oxygen levels drop, and could prove to be a very important target for drug development, as treatments evolve for diseases, such as cancer, heart disease and stroke, in which hypoxia is a central aspect.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, growing evidence showed that the strong cell–cell contacts of tumor spheroids in combination with dense ECM deposition is responsible for chemoresistance by posing a physical barrier to the penetration of chemotherapeutics and immune cells similar to in vivo.[ 48 ]”
From 3D Biomimetic Models to Reconstitute Tumor Microenvironment In Vitro: Spheroids, Organoids, and Tumor‐on‐a‐Chip (2023) · cites this paper as [48]
Citations
Cites
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Hypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177 · cited 1×
“Most importantly, overexpression of HIF-1α or HIF-2α have been implicated as poor prognostic indicators for a variety of tumour”
BackgroundHIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502
Cellular and developmental control of O 2 homeostasis by hypoxia-inducible factor 1α
Iyer, N. V., Kotch, L. E., Agani, F., Leung, S. W., Laughner, E., Wenger, R. H., Gassmann, M., Gearhart, J. D., Lawler, A. M., Yu, A. Y., et al. (1998) · Genes & Development · doi:10.1101/gad.12.2.149 · Cited by 2,476 · cited 1×
“Although the role of HIF-1α in human tumours remains correlative, in transplanted tumours in immunodeficient mice, loss of HIF-1α or HIF-1β results in reduced tumour growth, decreased angiogenesis and increased responsiveness to radiotherap”
BackgroundHuang, L. E., Gu, J., Schau, M., & Bunn, H. F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.7987 · Cited by 2,113
Research works printed but not linked: 1
- Flamme, I., Frolich, T. & Risau, W. Molecular mechanisms of vasculogenesis and embryonic angiogenesis. J. Cell. Physiol. 173, 206–210 (1997). · DOI · Paper page
Cited by
Items 101–200 of 671
(Aryloxyacetylamino)benzoic Acid Analogues: A New Class of Hypoxia-Inducible Factor-1 Inhibitors
Lee, K., Lee, J. H., Boovanahalli, S. K., Jin, Y., Lee, M., Jin, X., Kim, J. H., Hong, Y.-S., & Lee, J. J. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0610292 · Cited by 137
Krishnan, A. V., & Feldman, D. (2009) · Endocrine Related Cancer · doi:10.1677/erc-09-0139 · Cited by 139
Two transactivation mechanisms cooperate for the bulk of HIF‐1‐responsive gene expression
Kasper, L. H., Boussouar, F., Boyd, K. L., Xu, W., Biesen, M. A., Rehg, J. E., Baudino, T. A., Cleveland, J. L., & Brindle, P. K. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600846 · Cited by 152
“The closely related HIF-1a and HIF-2a are crucial for the physiological adaptation to hypoxia that requires the in- creased expression of genes involved in glucose metabolism, angiogenesis, hematopoiesis, cell survival, invasion, and vascular tone (Giaccia et al, 2003, 2004; Semenza, 2003).”
BackgroundHan, Z.-B., Ren, H., Zhao, H., Chi, Y., Chen, K., Zhou, B., Liu, Y.-J., Zhang, L., Xu, B., Liu, B., et al. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn066 · Cited by 133
“As a result of hypoxia and genetic mutations, HIF-1a is overexpressed in many human cancers (16, 17 ) including breast cancer (18,19).”
BackgroundCarrot and stick: HIF-α engages c-Myc in hypoxic adaptation
Huang, E. L. (2008) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402302 · Cited by 143
SAKAI, T., Sameshima, T., Matsufuji, M., Kawamura, N., Dobashi, K., & Mizui, Y. (2004) · The Journal of Antibiotics · doi:10.7164/antibiotics.57.173 · Cited by 131
Jang, G. Y., Jeon, J. H., Cho, S. Y., Shin, D. M., Kim, C. W., Jeong, E. M., Bae, H.-S., Kim, T. W., Lee, S. H., Choi, Y. H., et al. (2009) · Oncogene · doi:10.1038/onc.2009.342 · Cited by 146
“Moreover, HIF-1 inhibition noticeably suppresses tumor growth (Giaccia et al., 2003; Semenza, 2003), indicating that HIF-1 confers considerable growth advantages to tumor cells.”
BackgroundReal-Time Imaging of HIF-1α Stabilization and Degradation
Moroz, E., Carlin, S., Dyomina, K., Burke, S., Thaler, H. T., Blasberg, R., & Serganova, I. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005077 · Cited by 118
“For example, a number of anticancer drugs have been shown to inhibit HIF-1, but none of these drugs target HIF-1 directly and specifically [4,54,56,57,58,59,60,61,62,63],[64,65], [66], [63].”
BackgroundRole of hypoxia-inducible factor-1α as a cancer therapy target
Patiar, S., & Harris, A. L. (2006) · Endocrine-Related Cancer · doi:10.1677/erc.1.01290 · Cited by 125
Huang, S., Wu, M., Shun, C., Wang, H., Hsieh, C., Kuo, M., & Lin, J. (2005) · Journal of Biomedical Science · doi:10.1007/s11373-004-8177-5 · Cited by 130
“HIF-1a is primarily regulated by an oxygen concentration change [ 9 ] via degradation through the ubiquitin-proteasome pathway [11].”
BackgroundMethodInfluentialIdentification of a Novel Small Molecule HIF-1α Translation Inhibitor
Narita, T., Yin, S., Gelin, C. F., Moreno, C. S., Yepes, M., Nicolaou, K. C., & Van Meir, E. G. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3180 · Cited by 123
The phosphorylation status of PAS‐B distinguishes HIF‐1α from HIF‐2α in NBS1 repression
To, K. K. W., Sedelnikova, O. A., Samons, M., Bonner, W. M., & Huang, E. L. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601369 · Cited by 143
“…in recent years for both cancers and ischemic diseases by primarily focusing on inhibiting endogenous &2006 European Molecular Biology Organization The EMBO Journal VOL 25 | NO 20 | 2006 4791 HIF-a expression and delivering stable HIF-a for overexpression (Giaccia et al, 2003; Semenza, 2003).”
BackgroundFM19G11, a New Hypoxia-inducible Factor (HIF) Modulator, Affects Stem Cell Differentiation Status
Moreno-Manzano, V., Rodríguez-Jiménez, F. J., Aceña-Bonilla, J. L., Fustero-Lardíes, S., Erceg, S., Dopazo, J., Montaner, D., Stojkovic, M., & Sánchez-Puelles, J. M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.008326 · Cited by 115
Hypoxia inducible factor-1: a novel target for cancer therapy
Belozerov, V. E., & Van Meir, E. G. (2005) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000180116.85912.69 · Cited by 117
Merighi, S., Benini, A., Mirandola, P., Gessi, S., Varani, K., Leung, E., MacLennan, S., & Borea, P. A. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.03.020 · Cited by 133
Li, W., Zhou, Z., Zhou, X., Khoo, B. L., Gunawan, R., Chin, Y. R., Zhang, L., Yi, C., Guan, X., & Yang, M. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202202609 · Cited by 119
Harnessing the hypoxia-inducible factor in cancer and ischemic disease
Brahimi-Horn, M. C., & Pouysségur, J. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.10.013 · Cited by 122
Liu, P., Xie, X., Shi, X., Peng, Y., Ding, J., & Zhou, W. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b18112 · Cited by 115
Biological Activities of Emetine
Akinboye, E. S. (2011) · The Open Natural Products Journal · doi:10.2174/1874848101104010008 · Cited by 123
“Adaptation of cancer cells to hypoxia and their survival under these conditions have been attributed to the critical role played by certain genes whose expression is induced by hypoxia-inducible factor-1 [62].”
Song, H., He, R., Wang, K., Ruan, J., Bao, C., Li, N., Ji, J., & Cui, D. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.11.067 · Cited by 116
“Tumor-special hypoxia microenviroment provides us new pathway and idea for tumor targeting diagnosis and therapy, and leads to the current interest in the use of HIF-1a as a very important target for drug development [17,18].”
BackgroundLu, H., Lin, J., Xu, C., Sun, M., Zuo, K., Zhang, X., Li, M., Huang, H., Li, Z., Wu, W. H., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.334 · Cited by 121
The Role of Vitamin D in Cancer Prevention and Treatment
Krishnan, A. V., Trump, D. L., Johnson, C. S., & Feldman, D. (2012) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2012.03.014 · Cited by 113
“The proangiogenic effect of COX-2–generated PGE2 might be a result of its action to increase HIF-1a protein synthesis in cancer cells.104 Suppression of COX-2 expression by calcitriol therefore provides an important indirect mechanism by which calcitriol inhibits angiogenesis, in addition to its direct suppressive eff…”
BackgroundHodges, T. W., Hossain, C. F., Kim, Y.-P., Zhou, Y.-D., & Nagle, D. G. (2004) · Journal of Natural Products · doi:10.1021/np030514m · Cited by 111
Willam, C., Maxwell, P. H., Nichols, L., Lygate, C. A., Tian, Y., Bernhardt, W. M., Wiesener, M. S., Ratcliffe, P. J., Eckardt, K., & Pugh, C. W. (2006) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2006.04.009 · Cited by 129
“The role of these enzymes in regulating HIF and thus adaptive responses to hypoxia/ischemia makes them a potentially important target for intervention, particularly since manipulation of the HIF degradative pathway has been shown to affect patterns of gene expression in vivo [15–17].”
BackgroundTumor Cells Upregulate Normoxic HIF-1α in Response to Doxorubicin
Cao, Y., Eble, J. M., Moon, E., Yuan, H., Weitzel, D. H., Landon, C. D., Yu-Chih Nien, C., Hanna, G., Rich, J. N., Provenzale, J. M., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1345 · Cited by 111
“Hypoxia is one important factor for HIF-1 activation, VEGF expression and angiogenesis (1, 30, 39).”
Nangaku, M., Izuhara, Y., Takizawa, S., Yamashita, T., Fujii-Kuriyama, Y., Ohneda, O., Yamamoto, M., van Ypersele de Strihou, C., Hirayama, N., & Miyata, T. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.148551 · Cited by 110
Hypoxia and HIF-1α in chondrogenesis
Schipani, E. (2005) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2005.03.003 · Cited by 129
Intermittent Hypoxia Furthers the Rationale for Hypoxia-Inducible Factor-1 Targeting
Dewhirst, M. W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4744 · Cited by 108
“Fortunately, there is considerable interest in the development of drugs that can inhibit HIF-1 promoter activity (15).”
BackgroundChun, S. Y., Johnson, C., Washburn, J. G., Cruz-Correa, M. R., Dang, D. T., & Dang, L. H. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-293 · Cited by 109
“To date, high-throughput small-compound screens have identified several classes of anticancer agents that disrupt HIF-1a function; including inhibition of its transcriptional activity, synthesis, or protein stability [7,36].”
BackgroundTargeting hypoxic tumour cells to overcome metastasis
Bennewith, K. L., & Dedhar, S. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-504 · Cited by 109
“There are a number of small molecule inhibitors of HIF1a (the hypoxia-responsive a-subunit of HIF-1) that have been identified [20,21] including topotecan [22], YC-1 [23], and PX-478 [24].”
Kaluz, S., Kaluzová, M., & Stanbridge, E. J. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00552-06 · Cited by 108
“The role of HIF-1 in angiogenesis via up-regulation of vascular endothelial growth factor (VEGF) is well documented (13, 16), and it was also noted that HIF-1 in the presence of PI did not activate transcription (27, 55).”
BackgroundRole of the tumor microenvironment in the pathogenesis of gastric carcinoma
Chung, H. W., & Lim, J.-B. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i7.1667 · Cited by 111
Đạt, N. T., Jin, X., Lee, K., Hong, Y., Kim, Y. H., & Lee, J. J. (2008) · Journal of Natural Products · doi:10.1021/np800491u · Cited by 108
Uveal Versus Cutaneous Melanoma; Same Origin, Very Distinct Tumor Types
van der Kooij, M. K., Speetjens, F. M., van der Burg, S. H., & Kapiteijn, E. (2019) · Cancers · doi:10.3390/cancers11060845 · Cited by 114
“Hypoxia-inducible factor (HIF) plays a key role in tumorigenesis and metastasis in multiple types of cancer [87].”
BackgroundTo, K. K. W., & Huang, L. E. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504342200 · Cited by 106
The hypoxic tumor microenvironment and gene expression
Leo, C., Giaccia, A. J., & Denko, N. C. (2004) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2004.04.007 · Cited by 119
Self-citationFonslow, B. R., Carvalho, P. C., Academia, K., Freeby, S., Xu, T., Nakorchevsky, A., Paulus, A., & Yates, J. R. (2011) · Journal of Proteome Research · doi:10.1021/pr200304u · Cited by 102
“The detergent likely serves multiple functions: (1) disrupts stable protein interactions of protein complexes, (2) disrupts non-specific protein interactions of high abundance proteins to others, (3) denatures proteins and further exposes high affinity epitopes, and (4) minimizes non-specific hydrophobic protein-hexap…”
BackgroundTargeting Hypoxia-Inducible Factor-1-Mediated Metastasis for Cancer Therapy
Ma, Z., Wang, L. Z., Cheng, J.-T., Lam, S. T., Ma, X., Xiang, X., Wong, A. L., Goh, B. C., Gong, Q., Sethi, G., et al. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.7935 · Cited by 107
“These effects suppress tumor angiogenesis and metastasis (25).”
InfluentialHIF-1: structure, biology and natural modulators
Yang, C., Zhong, Z., Wang, S., Vong, C. T., Yu, B., & Wang, Y. (2021) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(21)60051-1 · Cited by 122
Mayer, A., Wree, A., Höckel, M., Leo, C., Pilch, H., & Vaupel, P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3566 · Cited by 101
“In hypoxia, this rapid adaptation is accomplished by a mechanism involving the interruption of the continuous proteasomal degradation of HIF-1 that takes place under normoxic conditions (5, 6 ). HIF-1 has, therefore, been considered as a candidate endogenous molecular hypoxia marker.”
BackgroundA Potassium-Dependent Oxygen Sensing Pathway Regulates Plant Root Hydraulics
Shahzad, Z., Canut, M., Tournaire‐Roux, C., Martinière, A., Boursiac, Y., Loudet, O., & Maurel, C. (2016) · Cell · doi:10.1016/j.cell.2016.08.068 · Cited by 102
“…metals and other cations (including K+) can regulate HIF-1a, a key regulator of anaerobic transcriptional response, at both mRNA and protein levels, and this process seems to bemostly related to growth adaptation of cancer cells to hypoxic environments (Giaccia et al., 2003; Lan et al., 2007).”
Mitochondrial cholesterol in health and disease.
García‐Ruiz, C., Marí, M., Colell, A., Morales, A., Caballero, F., Montero, J., Terrones, O., Basáñez, G., & Fernández-Checa, J. C. (2009) · PubMed · doi:10.14670/hh-24.117 · Cited by 111
“, 2005), it is conceivable that the accumulation of cholesterol within mitochondrial membranes may actually account or contribute to the known mitochondrial dysfunction of cancer cells, underlying the Warburg effect and dependence on glucolysis (Giaccia et al., 2003).”
BackgroundNovel Minicircle Vector for Gene Therapy in Murine Myocardial Infarction
Huang, M., Chen, Z., Hu, S., Jia, F., Li, Z., Hoyt, G. E., Robbins, R. C., Kay, M. A., & Wu, J. C. (2009) · Circulation · doi:10.1161/circulationaha.108.841155 · Cited by 100
Yu, Z., Liu, Y., Zhu, J., Han, J., Tian, X., Han, W., & Zhao, L. (2019) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1580616 · Cited by 101
Hypoxia-inducible factor modulates tubular cell survival in cisplatin nephrotoxicity
Tanaka, T., Kojima, I., Ohse, T., Inagi, R., Miyata, T., Ingelfinger, J. R., Fujita, T., & Nangaku, M. (2005) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00081.2005 · Cited by 108
“that maneuvers to activate HIF (9), including a method of”
MethodEndothelin-1 Stimulates Lymphatic Endothelial Cells and Lymphatic Vessels to Grow and Invade
Spinella, F., Garrafa, E., Castro, V. D., Rosanò, L., Nicotra, M. R., Caruso, A., Natali, P. G., & Bagnato, A. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-1879 · Cited by 99
“To study more in-depth the molecular mechanism by which ET-1 induces VEGF-C and VEGF-A, we analyzed the role of ET-1 and hypoxia on HIF-1a, the master transcriptional factor controlling VEGF production (32, 33).”
BackgroundAnalysis of gene expression changes in a cellular model of Parkinson disease
Ryu, E. J., Angelastro, J. M., & Greene, L. A. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.08.016 · Cited by 95
“However , in hypoxic conditions , there is insufficient oxygen to support hydroxylation of the critical proline residue , resulting in accumu - lation HIF - 1a to levels high enough to promote transcriptional actions on gene expression ( reviewed in Giaccia et al .”
Spinella, F., Rosanò, L., Castro, V. D., Decandia, S., Nicotra, M. R., Natali, P. G., & Bagnato, A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2606 · Cited by 107
Cyclic Peptide Screening Methods for Preclinical Drug Discovery
Li, X., Craven, T. W., & Levine, P. M. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01077 · Cited by 96
Lim, J.-H., Luo, C., Vazquez, F., & Puigserver, P. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2893-t · Cited by 92
“org Cancer Res; 74(13) July 1, 2014 3541”
InfluentialVHLinactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment
Rathmell, W. K., & Chen, S. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.1.63 · Cited by 107
“Thus, in the mTOR inhibited state HIF levels cannot be stabilized because the primary production of HIF is limited, as has been demonstrated elegantly in an in vitro study of HIF accumulation in response to hypoxic stimulation with and without rapamycin [85].”
BackgroundTian, L., Chen, Q., Yi, X., Wang, G., Chen, J., Ning, P., Yang, K., & Liu, Z. (2017) · Theranostics · doi:10.7150/thno.17381 · Cited by 100
“Such an obvious synergistic in vivo therapeutic outcome is found to be attributed to the PTX-induced tumor microenvironment modulation by greatly relieving tumor hypoxia [21, 22], which is known to have a crucial role in radiotherapy resistance [23-26].”
BackgroundGao, T., Li, J.-Z., Lü, Y., Zhang, C., Li, Q., Mao, J., & Li, L. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.02.044 · Cited by 100
Hypoxia-inducible factor-1: Regulatory mechanisms and drug development in stroke
Pan, Z., Ma, G., Kong, L., & Du, G. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105742 · Cited by 96
Razorenova, O. V., Finger, E. C., Colavitti, R., Chernikova, S. B., Boiko, A. D., Chan, C. K. F., Krieg, A., Bedogni, B., LaGory, E., Weissman, I. L., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011777108 · Cited by 87
“We hypothesized that CDCP1 gene expression might be induced by HIF, based on the fact that hypoxic exposure results in activation of HIF (2, 13) andVHL loss leads to the stabilization of HIF (14, 15).”
BackgroundSelf-citationMicrobiota-derived butyrate is an endogenous HIF prolyl hydroxylase inhibitor
Wang, R. X., Henen, M. A., Lee, J. S., Vögeli, B., & Colgan, S. P. (2021) · Gut Microbes · doi:10.1080/19490976.2021.1938380 · Cited by 95
Targeting solid tumors with non‐pathogenic obligate anaerobic bacteria
Taniguchi, S., Fujimori, M., Sasaki, T., Tsutsui, H., Shimatani, Y., Seki, K., & Amano, J. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01628.x · Cited by 85
Mohammed, K. A., Hossain, C. F., Zhang, L., Bruick, R. K., Zhou, Y.-D., & Nagle, D. G. (2004) · Journal of Natural Products · doi:10.1021/np049753f · Cited by 89
Baldo, B. A., & Pham, N. H. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9447-3 · Cited by 95
Natural Product-Based Inhibitors of Hypoxia-Inducible Factor-1 (HIF-1)
Nagle, D., & Zhou, Y.-D. (2006) · Current Drug Targets · doi:10.2174/138945006776054979 · Cited by 88
Zhou, Y., Kim, Y.-P., Li, X., Baerson, S. R., Agarwal, A. K., Hodges, T. W., Ferreira, D., & Nagle, D. G. (2004) · Journal of Natural Products · doi:10.1021/np040140c · Cited by 93
A3 Adenosine Receptors Modulate Hypoxia-inducible Factor-1a Expression in Human A375 Melanoma Cells
Merighi, S., Benini, A., Mirandola, P., Gessi, S., Varani, K., Leung, E., MacLennan, S., Baraldi, P. G., & Borea, P. A. (2005) · Neoplasia · doi:10.1593/neo.05334 · Cited by 84
“hibitor [57,61].”
Flavonoids induce HIF-1α but impair its nuclear accumulation and activity
Triantafyllou, A., Mylonis, I., Simos, G., Bonanou, S., & Tsakalof, A. K. (2007) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2007.10.050 · Cited by 99
“activity establishes HIF-1 as a potential therapeutic target [2,7,9,19–21], and identification of small molecules that affect HIF-1 as well as understanding the mechanism of their action is an important part of the pharmacological approach to the treatment of major diseases, such as ischemia and cancer [21– 23].”
BackgroundShi, X. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.080739 · Cited by 93
“The transcriptional complex hypoxia-inducible factor 1 (HIF-1) plays a key role in the cellular adaptations to the lack of oxygen supply.(44) In this study, using an immunohistochemical technique, the immunoreactivity of HIF-1 protein was examined under fluorescence confocal microscopy.”
BackgroundFunctions of the Per/ARNT/Sim Domains of the Hypoxia-inducible Factor
Yang, J., Zhang, L., Erbel, P. J. A., Gardner, K. H., Ding, K., Garcia, J. A., & Bruick, R. K. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501755200 · Cited by 87
Effect of hypoxia on Ad5 infection, transgene expression and replication
Shen, B. H., & Hermiston, T. W. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302448 · Cited by 86
The role of hypoxia inducible factor-1alpha in gynecological cancer
Seeber, L. M. S., Horrée, N., Vooijs, M., Heintz, A. P. M., van der Wall, E., Verheijen, R. H. M., & van Diest, P. J. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.05.003 · Cited by 88
“Although none of these have been hown to directly and specifically target HIF-1 [111,112], hey do decrease HIF-1A protein levels.”
BackgroundEffects of Histone Deacetylase Inhibitors on HIF-1
Liang, D., Kong, X., & Sang, N. (2006) · Cell Cycle · doi:10.4161/cc.5.21.3409 · Cited by 85
Yan, J., Zhou, B., Taheri, S., & Shi, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027798 · Cited by 84
“of HIF-1 have been observed in ischemic brains, regulating HIF1a induction and the genes induced by HIF-1 is a highly promising therapeutic strategy for cerebral ischemia [6,52-54] due”
BackgroundProspective strategies to enforce selectively cell death in cancer cells
Blagosklonny, M. V. (2004) · Oncogene · doi:10.1038/sj.onc.1207520 · Cited by 94
“Inhibitors of HIF-1 are currently under development (Giaccia et al., 2003; Semenza, 2003).”
BackgroundAging and Inflammation: Etiological Culprits of Cancer
Ahmad, A., Banerjee, S., Wang, Z. P., Kong, D., Majumdar, A. P. N., & Sarkar, F. H. (2009) · Current Aging Science · doi:10.2174/1874609810902030174 · Cited by 87
Breast Cancer Chemoprevention: Old and New Approaches
Cazzaniga, M., & Bonanni, B. (2012) · BioMed Research International · doi:10.1155/2012/985620 · Cited by 90
“For these reasons, HIF-1 is considered a potential target for cancer therapy, and, recently, many efforts to develop new HIF-1-targeting agents have been made [127–130].”
BackgroundImpact of Hypoxia on the Metastatic Potential of Human Prostate Cancer Cells
Dai, Y., Bae, K., & Siemann, D. W. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2011.04.027 · Cited by 80
“Under hypoxic conditions, HIF-1a is rapidly stabilized and functionally activated (10).”
BackgroundPreclinical evaluation of YC-1, a HIF inhibitor, for the prevention of tumor spreading
Shin, D. H., Kim, J.-H., Jung, Y.-J., Kim, K.-E., Jeong, J. M., Chun, Y.-S., & Park, J.-W. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.03.026 · Cited by 83
EGLN3 Prolyl Hydroxylase Regulates Skeletal Muscle Differentiation and Myogenin Protein Stability
Fu, J., Menzies, K. E., Freeman, R. S., & Taubman, M. B. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m608748200 · Cited by 92
microRNAs in Gliomas: Small Regulators of a Big Problem
Silber, J., James, C. D., & Hodgson, J. (2009) · NeuroMolecular Medicine · doi:10.1007/s12017-009-8087-9 · Cited by 83
“The transcription factor hypoxiainducible factor-1alpha (HIF-1a) is a well-established regulator of normoxia, angiogenesis, and tumorigenesis (Carmeliet et al. 1998; Zhong et al. 1999) and is a promising target for tumor therapeutics (Giaccia et al. 2003; Powis and Kirkpatrick 2004).”
BackgroundCrociani, O., Zanieri, F., Pillozzi, S., Lastraioli, E., Stefanini, M., Fiore, A., Fortunato, A., D’Amico, M., Masselli, M., Lorenzo, E. D., et al. (2013) · Scientific Reports · doi:10.1038/srep03308 · Cited by 90
RetractedGeng, H., Xue, C., Mendonca, J., Sun, X., Liu, Q., Reardon, P. N., Chen, Y., Qian, K., Hua, V. J., Chen, A. P., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07411-7 · Cited by 82
Tuttle, S. W., Maity, A., Oprysko, P. R., Kachur, A. V., Ayene, I. S., Biaglow, J. E., & Koch, C. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700327200 · Cited by 76
Sirtuin 1 attenuates nasal polypogenesis by suppressing epithelial-to-mesenchymal transition
Lee, M., Kim, D. W., Yoon, H., So, D., Khalmuratova, R., Rhee, C., Park, J., & Shin, H. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.07.026 · Cited by 80
A domain responsible for HIF-1α degradation by YC-1, a novel anticancer agent
Kim, H.-L., Yeo, E.-J., Chun, Y.-S., & Park, J.-W. (2006) · International Journal of Oncology · doi:10.3892/ijo.29.1.255 · Cited by 79
Nanomedicine-based combination anticancer therapy between nucleic acids and small-molecular drugs
Huang, W., Chen, L., Kang, L., Jin, M., Sun, P., Xin, X., Gao, Z., & Bae, Y. H. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.004 · Cited by 77
Hypoxia-inducible factor in cancer angiogenesis: Structure, regulation and clinical perspectives
Otrock, Z. K., Hatoum, H. A., Awada, A. H., Ishak, R. S., & Shamseddine, A. I. (2009) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2009.01.001 · Cited by 87
“[90] Giaccia A, Siim BG, Johnson RS.”
MethodDang, D. T., Chun, S. Y., Burkitt, K., Abe, M., Chen, S., Havre, P. A., Mabjeesh, N. J., Heath, E. I., Vogelzang, N. J., Cruz-Correa, M. R., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-1589 · Cited by 78
Kang, S., Gil, Y., Min, D., & Jang, H. (2020) · ACS Nano · doi:10.1021/acsnano.9b09974 · Cited by 76
Hypoxia, stem cells and bone tumor
Zeng, W., Wan, R., Zheng, Y., Singh, S. R., & Wei, Y. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.09.023 · Cited by 71
“In recent years, several small molecules have been identified, which can specifically target the HIF pathway [55-58].”
BackgroundTargeting the molecular basis for tumour hypoxia
Carroll, V. A., & Ashcroft, M. A. (2005) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399405009117 · Cited by 108
Ader, I., Malavaud, B. A., & Cuvillier, O. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0389 · Cited by 80
“to proteins involved in extracellular matrix remodeling, cell proliferation, or survival (5) leads toward a surviving phenotype with clinical aggressiveness.”
BackgroundFerroptosis‐related gene NOX4, CHAC1 and HIF1A are valid biomarkers for stomach adenocarcinoma
Xiao, R., Wang, S., Guo, J., Liu, S., Ding, A., Wang, G., Li, W., Zhang, Y., Bian, X., Zhao, S., et al. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17171 · Cited by 80
Abietane Diterpenes from Salvia miltiorrhiza Inhibit the Activation of Hypoxia-Inducible Factor-1
Đạt, N. T., Jin, X., Lee, J., Lee, D., Hong, Y., Lee, K., Kim, Y. H., & Lee, J. J. (2007) · Journal of Natural Products · doi:10.1021/np060482d · Cited by 75
Engineering in vitro microenvironments for cell based therapies and drug discovery
Cigognini, D., Lomas, A., Kumar, P., Satyam, A., English, A. R., Azeem, A., Pandit, A. S., & Zeugolis, D. I. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.06.007 · Cited by 84
Saururus cernuus lignans—Potent small molecule inhibitors of hypoxia-inducible factor-1
Hossain, C. F., Kim, Y.-P., Baerson, S. R., Zhang, L., Bruick, R. K., Mohammed, K. A., Agarwal, A. K., Nagle, D. G., & Zhou, Y.-D. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.05.191 · Cited by 78
“Currently, intense research efforts are directed at the discovery of small molecule HIF-1 inhibitors [1,11].”
BackgroundCindrova-Davies, T., van Patot, M. T., Gardner, L., Jauniaux, E., Burton, G. J., & Charnock-Jones, D. S. (2015) · MHR: Basic science of reproductive medicine · doi:10.1093/molehr/gau105 · Cited by 74
“The hypoxia-inducible factor (HIF) family of basic Helix–Loop–Helix transcription factors plays a key role in inducing these adaptive responses in other systems (Semenza et al., 1994; Forsythe et al., 1996; Semenza, 1999, 2001; Giaccia et al., 2003; Pugh and Ratcliffe, 2003).”
BackgroundHistone Deacetylase Inhibitors: The Epigenetic Therapeutics That Repress Hypoxia‐Inducible Factors
Chen, S., & Sang, N. (2010) · BioMed Research International · doi:10.1155/2011/197946 · Cited by 79
“Since HIF also regulate glucose metabolism, cell survival, microenvironment remodeling, and other alterations commonly required for tumor progression, they are considered as novel targets for cancer chemotherapy.”
Puppo, M., Battaglia, F., Ottaviano, C., Delfino, S., Ribatti, D., Varesio, L., & Bosco, M. C. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2059 · Cited by 76
“sion, treatment failure, and poor prognosis (9, 19–21), providing a rationale for targeting the HIF pathway as a strategy for cancer treatment (17, 22, 23).”
BackgroundZhou, Y.-D., Kim, Y.-P., Mohammed, K. A., Jones, D. K., Muhammad, I., Dunbar, D. C., & Nagle, D. G. (2005) · Journal of Natural Products · doi:10.1021/np050029m · Cited by 72
Hypoxia regulates SOX2 expression to promote prostate cancer cell invasion and sphere formation.
Bae, K., Dai, Y., Vieweg, J., & Siemann, D. W. (2016) · PubMed · Cited by 79
Fetal Growth Plate: A Developmental Model of Cellular Adaptation to Hypoxia
Provot, S., & Schipani, E. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1402.076 · Cited by 83
Roles of CUB domain‐containing protein 1 signaling in cancer invasion and metastasis
Uekita, T., & Sakai, R. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.02052.x · Cited by 72
Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer
Zhu, Y., Denhardt, D. T., Cao, H., Sutphin, P. D., Koong, A. C., Giaccia, A. J., & Le, Q. (2005) · Oncogene · doi:10.1038/sj.onc.1208800 · Cited by 79
“Accordingly, identification of molecular effectors of hypoxia will permit the development of molecular targeted therapies that is critical for improved therapeutic management of cancer patients (Giaccia et al., 2003).”
BackgroundSelf-citation
Metadata
- Authors
- Giaccia, A., Siim, B. G., & Johnson, R. S.
- Affiliations
- Stanford Medicine (US)
- University of Auckland (NZ)
- University of California San Diego (US)
- Corresponding author
- Johnson, Randall S.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2003-10-01
- Volume
- 2
- Issue
- 10
- Pages
- 803-811
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2075880922
- Cited by
- 631
- References
- 116
- Citations by year
- 2026: 9 · 2025: 14 · 2024: 10 · 2023: 21 · 2022: 26 · 2021: 19 · 2020: 30 · 2019: 14 · 2018: 26 · 2017: 16 · 2016: 20 · 2015: 20 · 2014: 27 · 2013: 30 · 2012: 29
- FWCI
- 3.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- HIF-1, hypoxia-inducible factor, hypoxia, therapeutic target, oxygen sensing, transcriptional regulation, cancer, heart disease, stroke, therapeutic targeting
- MeSH terms
- Animals, Cardiovascular Diseases, DNA-Binding Proteins, Gene Expression Regulation, Humans, Neoplasms, Nuclear Proteins, Oxygen, Transcription Factors, Drug Design, Hypoxia-Inducible Factor 1, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.